Good morning :)
Place Order
Add to Watchlist

Syngene International Ltd

SYNGENE

Syngene International Ltd

SYNGENE
Health CareLabs & Life Sciences Services
MidcapWith a market cap of ₹37,236 cr, stock is ranked 228
Low RiskStock is 1.78x as volatile as Nifty
928.300.02% (+0.15)
928.300.02% (+0.15)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareLabs & Life Sciences Services
MidcapWith a market cap of ₹37,236 cr, stock is ranked 228
Low RiskStock is 1.78x as volatile as Nifty

How to use scorecard? Learn more

Health CareLabs & Life Sciences Services
MidcapWith a market cap of ₹37,236 cr, stock is ranked 228
Low RiskStock is 1.78x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
77.278.750.13%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
57%
Analysts have suggested that investors can buy this stock

from 7 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.

Investor Presentation

View older 

Oct 23, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.49%, vs industry avg of 4.51%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 15.5% to 20.32%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 8.99%, vs industry avg of 5.9%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,484.901,900.702,164.802,283.902,657.003,263.803,579.203,563.10
Raw Materialssubtract395.20505.30518.60551.70770.60902.20873.602,491.80
Power & Fuel Costsubtract34.7041.3045.8057.4064.8069.2069.70
Employee Costsubtract379.60472.70580.40660.20718.10841.70888.70
Selling & Administrative Expensessubtract116.20123.10123.80107.80137.60196.70249.00
Operating & Other expensessubtract32.60146.40125.40135.40147.70248.70404.30
Depreciation/Amortizationsubtract131.40164.20219.30274.50309.70366.50425.90437.00
Interest & Other Itemssubtract22.7032.3034.6027.7024.1045.2047.2048.50
Taxes & Other Itemssubtract67.1083.80104.8064.3088.60129.20110.80103.90
EPS7.638.2910.3010.129.8911.5812.7011.99
DPS0.500.250.000.001.001.251.251.25
Payout ratio0.070.030.000.000.100.110.100.10

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Apr 27PDF
Jan 19PDF
Oct 20PDF
Jul 20PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 26PDF
Jan 23PDF
Oct 19PDF
Jul 20PDF
FY 2024

Annual report

PDF

Investor Presentation

Jul 26PDF
FY 2025

Annual Report Pending

Investor Presentation

Oct 23PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Syngene International Ltd73.018.750.13%
Divi's Laboratories Ltd103.8112.240.48%
Aarti Pharmalabs Ltd27.363.380.46%
Dishman Carbogen Amcis Ltd-26.540.72—

Price Comparison

Compare SYNGENE with any stock or ETF
Compare SYNGENE with any stock or ETF
SYNGENE
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.72%13.58%3.91%20.72%7.07%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep23.19%23.55%21.20%20.92%20.63%20.72%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Syngene International Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.7855%2.04%0.15%45/88 (+1)
ICICI Prudential Large & Mid Cap Fund - Growth - Direct Plan

Growth
0.6362%1.38%-0.29%65/119 (-4)
Nippon India Focused Equity Fund - Growth - Direct Plan

Growth
0.6154%2.70%0.27%16/36 (+3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Syngene International Ltd

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJun 28, 2024

Final
Final | Div/Share: ₹1.25

Dividend/Share

₹1.25

Ex DateEx Date

Jun 28, 2024

Cash Dividend

Ex DateEx DateJun 30, 2023

Special
Special | Div/Share: ₹0.75

Dividend/Share

₹0.75

Ex DateEx Date

Jun 30, 2023

Cash Dividend

Ex DateEx DateJun 30, 2023

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jun 30, 2023

Cash Dividend

Ex DateEx DateJun 30, 2022

Special
Special | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jun 30, 2022

Cash Dividend

Ex DateEx DateJun 30, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jun 30, 2022

News & Opinions
Earnings
Syngene International consolidated net profit declines 8.93% in the September 2024 quarter

Net profit of Syngene International declined 8.93% to Rs 106.10 crore in the quarter ended September 2024 as against Rs 116.50 crore during the previous quarter ended September 2023. Sales declined 2.10% to Rs 891.00 crore in the quarter ended September 2024 as against Rs 910.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales891.00910.10 -2 OPM %27.4727.92 - PBDT248.20262.70 -6 PBT137.30158.10 -13 NP106.10116.50 -9 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Syngene International approves change in management

The Board of Syngene International at its meeting held on 23 October 2024 has approved the following change in management: Resignation of Sibaji Biswas, Executive Director and Chief Financial Officer (Key Managerial Personnel) from the services of the Company with effect from 30 November 2024. Appointment of Deepak Jain as the Chief Financial Officer and a Key Managerial Personnel of the Company effective from 01 December 2024. Appointment of Dr. Jayashree Aiyar as Chief Scientific Officer and a member of the Executive Committee (Senior Management Personnel) of the Company effective from 23 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Syngene International to convene board meeting

Syngene International will hold a meeting of the Board of Directors of the Company on 23 October 2024Powered by Capital Market - Live

2 months agoCapital Market - Live

Syngene International and 4 other stocks close below VWAP

4 months agoEconomic Times

Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and Cyient

4 months agoEconomic Times
Syngene Q1 Earnings: In-Line Profits Recorded, What's The Growth Outlook Of Company In Future?
4 months agoET NOW
'Got Super Modern Laboratories In India': Syngene International MD & CEO
4 months agoNDTV Profit

Syngene Q1 Results: Net profit down 19% to ₹75.7 crore

4 months agoThe Hindu Businessline
Result Review | How were the Results for Petronet LNG Futures & Syngene Intl ?
4 months agoZee Business

Syngene Q1 Results: Net profit drops 19% to Rs 76 crore

4 months agoEconomic Times